Pegaspargase

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pegaspargase
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a695031
Pregnancy
category
  • US: C (Risk not ruled out)
ATC code L01XX24 (WHO)
Legal status
Legal status
Identifiers
CAS Number 130167-69-0 YesY
DrugBank DB00059 YesY
ChemSpider none
UNII 7D96IR0PPM YesY
Chemical and physical data
Formula C1377H2208N382O442S17
Molar mass 31731.9 g/mol
 NYesY (what is this?)  (verify)

Pegaspargase /pəˈɡæspərɡz/, trade name Oncaspar, is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation.

It is used in the treatment of acute lymphoblastic leukemia.[2][3]

See also[edit]

PEGylation

References[edit]

  1. ^ "UNM Cancer Center". Archived from the original on September 3, 2006. Retrieved 2007-08-28. 
  2. ^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708. 
  3. ^ Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics. 5 (6): 492–496.